NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
23,355.35 -936.14 (-3.85%)
Freeline Therapeutics Holdings plc (FRLN)
| Previous close | 0.7443 |
| Open | 0.7404 |
| Bid | 0.7220 x 800 |
| Ask | 0.7500 x 1200 |
| Day's range | 0.7200 - 0.7500 |
| 52-week range | 0.6500 - 15.4000 |
| Volume | |
| Avg. volume | 213,913 |
| Market cap | 26.359M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership team LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today reported financial results for the first quarter of 2022 and provided a business update. “We continue the transformation of Freeline to unlock its untapped value, focusing
- Globe Newswire
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 57,850 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcom
- Globe Newswire
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
Five abstracts accepted with new research and technology insights and data to further enhance AAV-based gene therapy candidatesLONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that will take place May 16-19, 2022 in Washington, D.C. The presentations will provide new insights and data
